echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Third generation EGFR-TKI ushered in the third domestic application for listing

    Third generation EGFR-TKI ushered in the third domestic application for listing

    • Last Update: 2019-12-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 10, the third generation EGFR-TKI "efutinib" independently developed by Jiangsu Elis biomedical Co., Ltd was accepted by the drug Audit Center (acceptance No.: cxhs1900039) Source: CDE official website of China's third generation EGFR-TKI, only ashitinib of AstraZeneca is listed, but there is no domestic third generation listing at present, but avitinib of Eisen medicine and ometinib of hausen have submitted listing applications Alfetinib mesylate (ast2818) is an irreversible and selective third-generation EGFR inhibitor independently developed by Shanghai Ellis Pharmaceutical Technology Co., Ltd It has significant inhibitory activity on egfrt790m + resistant mutations and EGFR sensitive mutations The results of preclinical and existing clinical studies show that: 1 Efetinib mesylate is a double targeted EGFR inhibitor; 2 The objective response rate (ORR) of efetinib mesylate in patients with locally advanced or metastatic non-small cell lung cancer with egfrt790m + mutation is higher than that of azd9291; 3 Efetinib mesylate is 20-240 It has good tolerance within the dose range of mg / day, and the incidence of adverse reactions in gastrointestinal tract and skin is significantly lower than that of tiresar (azd9291); 4 Efetinib mesylate has a strong ability to penetrate the blood-brain barrier, which may be effective for non-small cell lung cancer patients with brain metastasis Efetinib mesylate is intended to be used in the treatment of non-small cell lung cancer with egfrt790m + mutation and EGFR sensitive mutation The current results show that efetinib mesylate has significant antitumor effect and better safety, and it is expected to become the best third generation EGFR inhibitor in the same drugs The project has obtained major special support from Guozhong science and Technology Co., Ltd., "major new drug creation" Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.